Survodutide and MASH: Why This Drug Targets Liver Fat

Survodutide

62% MASH resolution

In the Phase 2 NEJM trial, 62% of patients receiving survodutide 4.8 mg achieved MASH resolution without worsening fibrosis, compared to 14% on placebo.

Sanyal et al., NEJM, 2024

Sanyal et al., NEJM, 2024

View as image

Metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH, affects an estimated 5% of adults globally. It is the inflammatory stage of fatty liver disease, where fat accumulation triggers hepatocyte damage, inflammation, and fibrosis that can progress to cirrhosis and liver failure. Until recently, no drug was specifically approved to treat it. GLP-1 agonists like semaglutide showed promise, but their effects on liver fat were secondary to weight loss. Survodutide takes a different approach. By activating both the GLP-1 receptor and the glucagon receptor simultaneously, it targets liver fat metabolism directly through glucagon's hepatic effects while also providing the appetite suppression and insulin sensitization of GLP-1 signaling. For a broader look at survodutide's mechanism, see our overview of survodutide as a GLP-1/glucagon agonist.

The Phase 2 trial published in the New England Journal of Medicine in 2024 produced the clearest evidence yet that glucagon receptor activation adds something that GLP-1 alone does not provide for liver disease.^[1] Up to 62% of patients achieved MASH resolution without worsening fibrosis. These results earned survodutide FDA Breakthrough Therapy designation and launched the Phase 3 SYNCHRONIZE program.

Why Glucagon Matters for Liver Fat

The glucagon receptor is highly concentrated in hepatocytes. When glucagon binds it, the liver responds by increasing fatty acid oxidation (burning fat for energy), decreasing lipogenesis (making less new fat), increasing ketogenesis, and stimulating amino acid catabolism.^[2] These are precisely the metabolic pathways dysregulated in MASH.

In MASH, the liver accumulates triglycerides because lipogenesis outpaces fat oxidation. Inflammatory cascades follow: lipotoxic intermediates damage hepatocytes, stellate cells activate and produce collagen (fibrosis), and immune cells infiltrate the tissue. Glucagon receptor activation directly counteracts the root metabolic imbalance by shifting the liver's energy metabolism from fat storage to fat burning.

Pure GLP-1 agonists reduce liver fat primarily through weight loss and improved insulin sensitivity. These effects are real, semaglutide reduced liver fat by approximately 30% in the NASH trial, but they reach the liver indirectly. Survodutide's glucagon component adds a direct hepatic signal that operates independently of body weight changes.

Thomas et al. (2024) profiled survodutide's pharmacological fingerprint and confirmed that glucagon receptor engagement produces measurable biomarker changes distinct from GLP-1 signaling: elevated amino acid catabolism markers, increased circulating FGF21 (a hepatokine involved in fat metabolism), and shifts in bile acid composition.^[2] These markers were absent or minimal with pure GLP-1 agonists, confirming that survodutide's liver effects are not simply "more weight loss."

For a detailed comparison of survodutide against single-receptor agonists, see our article on how survodutide differs from other dual agonists.

The NEJM Phase 2 Trial: Design and Results

Sanyal et al. (2024) enrolled 295 adults with biopsy-confirmed MASH and liver fibrosis stages F1 through F3 at 65 sites across 12 countries.^[1] Participants were randomized to receive once-weekly subcutaneous survodutide at 2.4 mg, 4.8 mg, or 6.0 mg, or placebo for 48 weeks. The first 24 weeks used rapid dose escalation; the remaining 24 weeks maintained the target dose.

MASH Resolution

The primary endpoint was histological improvement in MASH without worsening of fibrosis. Results by dose:

• 2.4 mg: 47% achieved MASH resolution (vs. 14% placebo)
• 4.8 mg: 62% achieved MASH resolution (vs. 14% placebo)
• 6.0 mg: 43% achieved MASH resolution (vs. 14% placebo)

The inverted dose-response (6.0 mg performing worse than 4.8 mg) was attributed to higher rates of discontinuation and GI side effects at the top dose. More patients in the 6.0 mg group dropped out before the 48-week biopsy, which may have biased the per-protocol analysis.

Liver Fat Reduction

A reduction in liver fat content of at least 30% (measured by MRI-derived proton density fat fraction) occurred in:

• 2.4 mg: 63%
• 4.8 mg: 67%
• 6.0 mg: 57%
• Placebo: 14%

Fibrosis Improvement

Improvement in fibrosis by at least one stage (assessed by liver biopsy) occurred in 34-36% of survodutide-treated patients versus 22% on placebo. While statistically significant, the fibrosis improvement margin was narrower than the MASH resolution margin, suggesting that reversing fibrosis requires longer treatment or additional mechanisms beyond fat reduction.

Weight Loss

Survodutide produced substantial weight loss alongside its hepatic effects: approximately 10-15% body weight reduction across dose groups versus 2% for placebo. The weight loss data from a separate obesity-focused trial were more precisely characterized by Le et al. (2024).^[3]

Separating Liver-Specific Effects from Weight Loss

A critical question: is survodutide's MASH benefit simply a consequence of its weight loss, or does glucagon receptor activation add something liver-specific?

Several lines of evidence support a direct hepatic mechanism beyond weight loss:

Head-to-head comparison with weight loss alone. In the semaglutide NASH trial (Phase 2), semaglutide at 0.4 mg daily produced approximately 13% weight loss and 59% MASH resolution. Survodutide at 4.8 mg weekly produced similar weight loss (approximately 12-15%) but 62% MASH resolution with a different metabolic signature. The hepatic biomarker profile (FGF21 elevation, amino acid changes) with survodutide was distinct from semaglutide's profile.

Dose-independent liver fat reduction. Bluher et al. (2024) analyzed dose-response relationships for survodutide across metabolic parameters.^[4] Liver fat reduction was robust even at the 2.4 mg dose, where weight loss was less pronounced. This suggests that the glucagon-mediated hepatic fat oxidation operates at lower doses than required for maximal appetite suppression.

Pharmacological profiling. Thomas et al. (2024) showed that survodutide's glucagon receptor engagement produced liver-specific biomarker shifts (particularly in amino acid catabolism and FGF21) that correlated with MASH improvement independently of body weight change.^[2]

Earlier Evidence: The Phase 1b Liver Data

Before the Phase 2 MASH trial, Lawitz et al. (2024) published Phase 1b data showing survodutide's effects on liver fat in patients with non-alcoholic fatty liver disease.^[5] Over 16 weeks, survodutide reduced liver fat content by up to 64% measured by MRI-PDFF. The magnitude of liver fat reduction exceeded what would be expected from the degree of weight loss alone, providing early evidence for a direct hepatic mechanism.

This study also established the pharmacokinetic profile in the target population. Survodutide's half-life supported once-weekly dosing, and the dose-escalation approach reduced GI side effects compared to starting at full dose.

The GI Side Effect Profile

Survodutide's tolerability is its primary clinical challenge. In the Phase 2 MASH trial, gastrointestinal adverse events were substantially more frequent with survodutide than placebo:^[1]

• Nausea: 66% vs. 23% placebo
• Diarrhea: 49% vs. 23% placebo
• Vomiting: 41% vs. 4% placebo
• Constipation: 22% vs. 14% placebo

These rates are higher than reported for semaglutide (approximately 44% nausea) or tirzepatide (approximately 25-33% nausea). The glucagon component likely contributes to the increased GI burden, though the rapid dose-escalation protocol used in this trial may have exacerbated it. The Phase 3 SYNCHRONIZE program uses a slower dose-escalation schedule designed to improve tolerability.

Discontinuation due to adverse events occurred in 6-10% of survodutide-treated patients versus 3% on placebo. For context on GI effects across the GLP-1 class, see our article on nausea on semaglutide or tirzepatide.

Where Survodutide Fits Among MASH Treatments

The MASH treatment landscape is evolving rapidly. Resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, was approved by the FDA in March 2024 as the first drug specifically for MASH with moderate to advanced fibrosis. Survodutide and several other peptide-based approaches are in late-stage development:

Retatrutide, Eli Lilly's triple agonist (GLP-1/GIP/glucagon), showed 86% relative liver fat reduction in Phase 2 data. It adds GIP receptor activation to the dual agonist approach.

Pemvidutide, another GLP-1/glucagon dual agonist from Altimmune, reported Phase 2b MASH data in 2025 with similar MASH resolution rates.

Tirzepatide (GLP-1/GIP dual agonist) showed MASH resolution in its SYNERGY-NASH Phase 2 trial, though its mechanism lacks the glucagon-mediated hepatic fat oxidation that survodutide provides.

Survodutide's differentiator is the specificity of its glucagon receptor engagement for liver fat. Whether that translates to superior fibrosis regression (the outcome that matters most for long-term liver disease progression) is the question the Phase 3 SYNCHRONIZE program aims to answer. The program includes trials in MASH with fibrosis (SYNCHRONIZE-1), MASH with cirrhosis (SYNCHRONIZE-3), and MASH with type 2 diabetes (SYNCHRONIZE-4).

Brain-Level Mechanisms: Not Just a Liver Drug

Zimmermann et al. (2026) used neuronal activation mapping in animal models to show that survodutide acts on circumventricular organs in the brain, regions where the blood-brain barrier is absent or reduced, allowing circulating peptides to directly engage neural receptors. Survodutide activated neuronal populations in the area postrema (involved in nausea and appetite regulation) and the nucleus of the solitary tract (a central integration point for satiety signals). The dual activation pattern differed from pure GLP-1 agonists, with glucagon receptor engagement producing additional activation in hypothalamic regions linked to energy expenditure regulation. This brain-level data helps explain both survodutide's appetite suppression and its higher nausea rates: the glucagon component amplifies signaling in the same brainstem regions that trigger nausea.

The Paradox of Adding Glucagon

Glucagon raises blood glucose. That is its primary endocrine function. Adding glucagon receptor agonism to a drug intended for patients who frequently have type 2 diabetes seems counterintuitive.

Survodutide manages this paradox through the GLP-1 component. GLP-1 receptor activation increases insulin secretion, suppresses glucagon secretion from alpha cells, and improves insulin sensitivity. In the Phase 2 diabetes study, Bluher et al. (2024) showed that survodutide reduced HbA1c in a dose-dependent manner, with reductions of 0.6-1.0% across dose groups.^[4] The GLP-1 effect on glucose homeostasis outweighed the glucagon effect, resulting in net glucose improvement.

This balance is maintained at the doses studied so far. Whether it holds in all patient populations, particularly those with advanced diabetes and impaired beta-cell reserve, remains an open question for Phase 3 data.

The Bottom Line

Survodutide's dual GLP-1/glucagon agonism directly targets hepatic fat metabolism through glucagon receptor activation, producing MASH resolution rates of up to 62% in Phase 2 data. The glucagon component adds liver-specific effects (increased fatty acid oxidation, FGF21 elevation, amino acid catabolism) that pure GLP-1 agonists do not produce. GI side effects are higher than competing drugs, a limitation the Phase 3 program aims to address with slower dose escalation. The SYNCHRONIZE Phase 3 program will determine whether these results translate to fibrosis regression and clinical outcomes in larger, longer trials.

Frequently Asked Questions

What is survodutide used for?

Survodutide is an investigational drug being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. It is a dual GLP-1/glucagon receptor agonist administered as a once-weekly subcutaneous injection. In Phase 2 trials, survodutide achieved 47-62% MASH resolution versus 14% placebo (Sanyal et al., NEJM, 2024) and up to 14.9% body weight reduction versus 2.8% placebo (Le et al., Lancet Diabetes Endocrinol, 2024). It is not yet approved by any regulatory agency.

How does survodutide work on the liver?

Survodutide activates the glucagon receptor on hepatocytes, which increases fatty acid oxidation (fat burning), decreases de novo lipogenesis (fat production), and stimulates amino acid catabolism. These direct hepatic effects reduce liver fat content by shifting the liver's metabolic balance from fat storage to fat utilization. The GLP-1 component adds appetite suppression, insulin sensitization, and glucose control. Biomarker profiling confirms that the liver effects are distinct from weight loss alone (Thomas et al., 2024).

Is survodutide better than semaglutide for fatty liver?

Direct head-to-head comparison data does not exist. In separate Phase 2 trials, survodutide achieved 62% MASH resolution at 4.8 mg weekly (Sanyal et al., NEJM, 2024), while semaglutide achieved 59% MASH resolution at 0.4 mg daily. Survodutide's glucagon component produces liver-specific biomarker changes (FGF21 elevation, amino acid catabolism) absent with semaglutide, suggesting a direct hepatic mechanism beyond weight loss. Whether this translates to superior fibrosis outcomes will require Phase 3 data from both drugs.

What are survodutide side effects?

In the Phase 2 MASH trial, the most common side effects were gastrointestinal: nausea (66% vs. 23% placebo), diarrhea (49% vs. 23% placebo), vomiting (41% vs. 4% placebo), and constipation (22% vs. 14% placebo). These rates are higher than reported for semaglutide or tirzepatide. Discontinuation due to side effects occurred in 6-10% of patients. The Phase 3 SYNCHRONIZE program uses a slower dose escalation schedule to improve tolerability (Sanyal et al., NEJM, 2024).

When will survodutide be approved?

Survodutide received FDA Breakthrough Therapy designation for MASH in 2024 based on Phase 2 results. The Phase 3 SYNCHRONIZE program includes multiple trials expected to read out data beginning in 2026-2027. If Phase 3 results are positive, the Breakthrough Therapy designation could accelerate FDA review. No specific approval date has been announced. Survodutide is developed by Boehringer Ingelheim in collaboration with Zealand Pharma.

What is the difference between survodutide and tirzepatide for liver disease?

Survodutide activates GLP-1 and glucagon receptors, while tirzepatide activates GLP-1 and GIP receptors. The key difference for liver disease is glucagon versus GIP. Glucagon receptor activation directly increases hepatic fat oxidation and decreases lipogenesis, providing liver-specific metabolic effects. GIP's effects on the liver are less direct. Both drugs show MASH resolution in Phase 2 trials, but survodutide's glucagon-mediated biomarker profile suggests a distinct hepatic mechanism. Phase 3 data will determine whether this translates to different fibrosis outcomes.